A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder in children that may persist into adulthood. Lisdexamfetamine dimesylate (LDX) is approved in many countries for ADHD treatment in children, adolescents, and adults. OBJECTIVES: Estimate the cost-effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimovetz, Evelina A., Joseph, Alain, Ayyagari, Rajeev, Mauskopf, Josephine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773633/
https://www.ncbi.nlm.nih.gov/pubmed/28093662
http://dx.doi.org/10.1007/s10198-016-0864-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773633/
https://www.ncbi.nlm.nih.gov/pubmed/28093662
http://dx.doi.org/10.1007/s10198-016-0864-4

Ejemplares similares